Orano Med Provides Half-Year Progress Report and Business Outlook

Orano Med Provides Half-Year Progress Report and Business Outlook

Orano Med, a subsidiary of the Orano Group specializing in nuclear medicine, today provided an overview of its activities and progress made during the first half of 2026, along with a business outlook for the remainder of the year. The update covers the company's key areas of operations, including corporate developments, clinical progress and preclinical research as well as industrial activities, and outlines priorities and initiatives for the second half of 2026.

Frederic Desdouits, CEO of Orano Med commented: “Since joining Orano Med in April, I've seen strong progress across all key areas of our business. In the past six months, we’ve significantly expanded our clinical pipeline, with four active lead-212 clinical studies underway, conducted by Orano Med or our partners. With our newly inaugurated R&D center in France complementing our US research hub, we have capability to further accelerate drug candidate development. On the industrial side, we are ramping up thorium-228 production at our pilot facility, and the EUR 125 million loan from the European Investment Bank will support continued investment into our industrial platform's development. Our GMP facilities, the ATLabs in Indianapolis and Valenciennes, remain on schedule to supply clinical doses in the US and Europe. H1 2026 marked a period of meaningful progress, and we look forward to building on this momentum.”